Reported Monday, Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Show Survival Improvement Versus Chemotherapy In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial
Reported Monday, Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Show Survival Improvement Versus Chemotherapy In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial
週一報道，在Tropion-Lung01 3期試驗中，第一三共和阿斯利康的Datopotamab Deruxtecan顯示，與化療相比，晚期非鱗狀非小細胞肺癌患者的存活率有所改善
- In the overall trial population, survival results numerically favored Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan but did not reach statistical significance
- TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the overall trial population
- Results support applications currently under review by regulatory authorities globally including the U.S. and EU
- 在整個試驗人群中，存活結果在數字上有利於第一三共和阿斯利康的datopotamab deruxtecan，但沒有達到統計學意義
- Tropion-Lung01 此前在整個試驗人群中達到無進展存活率的雙重主要終點
- 結果支持包括美國和歐盟在內的全球監管機構目前正在審查的申請
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。